INTRODUCTION
Swelling and tenderness in the small joints are associated with radiological damage in these joints in RA patients. 1, 2 Clinical synovitis of the large joints, especially the knees, has also been shown to be predictive of small joint damage, possibly because the presence of a large area of inflamed synovium is correlated with higher systemic levels of pro-inflammatory cytokines. 3 One would assume that large joint inflammation results in local joint damage, but to our knowledge this has never been investigated. In older cohorts, large joint damage is associated with worse functional ability. 4, 5 It is unclear whether this association is still present in patients optimally treated with treatment to target. This we investigated in a large cohort of patients with systematic joint evaluations during 8 years of targeted treatment aiming at low disease activity.
METHODS

Patients
Data from patients from the BeSt study who had radiographs after 8 years of follow-up of ≥2 different large joints were used. The BeSt study is a multi-center randomized controlled trial, in which 508 patients with recent onset RA according to the 1987 American College of Rheumatology criteria were included. All patients gave their written informed consent and the study was approved by the local medical ethics committees of all participating centers. Patients were treated according to a dynamic protocol starting with initial methotrexate monotherapy (sequential or stepwise), combination therapy with prednisolone or combination therapy with infliximab, with treatment adjustments based on assessments of the disease activity score (DAS) performed every 3 months. Treatment was intensified or changed in case of insufficient response (DAS >2.4). If the DAS was ≤2.4 for ≥6 months, medication was tapered to maintenance dose. Starting 2 years after inclusion, patients on monotherapy maintenance dose with a DAS <1.6 for ≥6 months were allowed to taper and stop their last disease modifying anti-rheumatic drug (DMARD). A more detailed description of the study protocol has been published previously. 6 
Study endpoints
Tenderness in the shoulders, elbows, wrists, hips, knees and ankles was assessed every three months by trained research nurses, blinded for treatment allocation, using the Ritchie Articular Index (RAI). It was recoded for the purpose of these analyses as absence of tenderness (RAI 0), or presence (RAI 1, 2 or 3). With the exception of the hips, joints were also scored for swelling (absent or present). Clinical data from the first 2 years after 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39 starting treatment was chosen because disease activity was highest in these years while radiological damage in the small joints was still relatively low. Thus it is unlikely that symptoms in the large joints were due to radiological damage but we have no baseline radiographs of the large joints to confirm this. Mostly due to logistic limitations, only of 290 patients out of 347 patients still in follow-up after 8 years radiographs of the large joints were made. Missing data of at least one joint were found in 76 patients, either because no radiographs were available or because they had prosthesis and no information about the reason for the prosthesis was present. The distribution of missing joints has been published previously. 7 At baseline, patients still in follow-up who did not have large joint radiographs were statistically significantly older (56 vs 52 years), but they had slightly better functional ability (mean HAQ 1.1 vs 1.3). Other baseline characteristics were not statistically different (data not shown). Joint damage in the shoulders, elbows, wrists, hips, knees and ankles consistent with effects of rheumatoid inflammation or secondary arthritis was scored by an experienced musculoskeletal radiologist (HK) using the Larsen score for large joints, 8 ranging from 0 (no damage) to 5 (total destruction).
Ten percent of all joints were rescored to assess reliability, with the same score in 93%. A total Larsen score of all 12 joints (maximum 60) was calculated for all patients who had a maximum of 2 missing joint scores. Functional ability was assessed using the Health Assessment Questionnaire. Disability was defined as a HAQ ≥1.9.
Statistical analysis
The relation between symptoms of local inflammation in the first 2 years of treatment and any local joint damage after 8 years (defined as a Larsen score of ≥1, to include minimal damage into the analysis) was evaluated for 'ever signs of inflammation' and next for 'persistent signs of inflammation' by calculating attributable risks. Attributable risks indicate the fraction of added risk in the presence of a certain risk factor, but do not imply causality. Next, we calculated odds ratios (ORs) using generalized estimating equations with an exchangeable covariance structure. This type of analysis takes into account the correlation between different joints within the same patient. The presence or absence of swelling and tenderness was categorized into 4 categories: no swelling or tenderness, tenderness but not swelling, swelling but no tenderness and swelling and tenderness. As swelling could not be determined in the hips, these were not included in the analyses. The models were adjusted for baseline age, erythrocyte sedimentation rate (ESR), body mass index (BMI), gender, treatment strategy, rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA) or a combination of these variables and time-averaged DAS of year 0-2. The correlations between HAQ and total Larsen score and between HAQ and DAS after 8 years of treatment were assessed using the Spearman's rank correlation test. Then, the association between having damage in any large joint (total Larsen score ≥1) and the HAQ score was explored using a linear regression 3 4 5 6 7 8 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39   25 Large joint synovitis and local large joint damage 2 analysis. Subsequently we used logistic regression analysis to investigate if patients with a total Larsen score in the highest tertile had a greater risk of a HAQ score ≥1 compared to patients with a total Larsen score in the lowest tertile. Both estimates were adjusted for DAS at year 8, baseline age, ESR, BMI, gender, treatment strategy, the presence of RF or ACPA, or a combination of these variables. DAS over 8 years was compared for patients with and without any large joint damage using linear mixed models with a Toeplitz covariance structure, adjusted for baseline age, DAS, BMI, gender, treatment strategy, the presence of RF or ACPA, or a combination of these variables. This analysis was repeated to compare systemic inflammation over 8 years for these patients, with ESR as outcome, adjusted for the same variables, but with baseline ESR instead of baseline DAS.
RESULTS
Radiographs of the large joints were available in 290 patients, 84% of all patients still under follow-up in the BeSt study.(baseline characteristics in table 1) Patients with radiological data still in follow-up were younger than the 218 patients no longer in follow-up or without radiographs (mean age at baseline 52 versus 58, p<0.001) and more often treated with combination therapy with infliximab (30 versus 19%) when compared to combination therapy with prednisolone (24 versus 29%, p=0.01) and stepup monotherapy (21 versus 28%, p=0.003). They had a baseline DAS of 4.3 compared to A Larsen score ≥1 in at least 1 joint was found in 64% of 290 patients, a Larsen score of ≥2 in at least 1 joint in 37%. Tenderness at least once was observed in 60% of all large joints, at least twice consecutively in 27%. Swelling was observed at least once in 46% and at least twice consecutively in 15%. Patients with radiological damage of large joints (Larsen score ≥1 in at least one large joint) were older at baseline than patients without (54 years old compared to 48, p<0.001) and they had more small joint damage, with a median Sharp-van der Heijde score (SHS) of 3.0, compared to 0.8 (p<0.001).
Swelling and tenderness
Swelling, either in the presence or absence of tenderness showed an association with any local joint damage after 8 years, with ORs of 2.5 (95% CI 1.7;3.6) and 2.0 (95% CI 1.1;3.6) respectively. (table 3) The association between tenderness without swelling and any local damage was less strong: OR 1.4 (95% CI 0.97;2.1). These associations were independent of baseline age, ESR, BMI, gender, treatment strategy, rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA) or both and time-averaged DAS of year 0-2. Persistent swelling and/or persistent tenderness (present during at least 2 consecutive visits) in the first two years showed an even stronger association with any local joint damage after 8 years. Other independent predictors of large joint damage after 8 years in this model were higher baseline ESR (OR 1.01, 95% CI 1.01;1.02) and the presence of RF or ACPA (OR 2.2, 95% CI 1.3;3.8), or both (OR 2.5, 95% CI 1.5;4.1). 
Functional ability and disease activity
The median total Larsen score, which could be calculated for 262/290 patients, was 1 (IQR 0-4). Total Larsen score showed a weak, but significant correlation (Rs 0.2, p=0.001) with the HAQ score at year 8. In comparison, small joint damage (total Sharp-van der Heijde score) at year 8 did not show a correlation with the HAQ score in these patients. The DAS showed a correlation with the HAQ score at year 8 of 0.5 (p <0.001). The difference in HAQ score after 8 years between patients with and without joint damage in ≥1 joint was not clinically relevant: 0.15 (95% CI 0.02;0.28). Patients with a higher total Larsen score (highest tertile, Larsen score ≥4) had a higher risk of functional impairment Table 2 : number of joints with swelling and/or pain at least once in years 0-2 per joint No swelling or pain 130  128  75  62  101  88  44  39  94  66   Pain no swelling  56  75  61  59  63  60  38  44  140  156   Swelling no pain  20  16  13  17  15  22  10  12  5  5   Pain and swelling  84  71  141  152  111  120  198  195  51  63 R right, L left 
DISCUSSION
Swelling, persistent swelling and persistent tenderness in individual large joints during the first 2 years of treatment in patients with recent onset RA were independently associated with joint damage after 8 years in the same joints. Although there was little radiological damage in the large joints, large joint damage showed a statistically significant association with functional ability, whereas small joint damage did not. The association that was found between clinical signs of synovitis and joint damage in large joints is in line with what was found for damage in small joints.
1, 2 Local suppression of inflammation may also result in local prevention of damage. This was suggested by the finding that less erosions on MRI occurred in metacarpophalangial joints that were treated with intra-articular corticosteroids on top of systemic treatment. 10 Other independent predictors of later large joint damage were higher baseline ESR as indi- cation of systemic inflammatory activity, and presence of auto-antibodies ACPA and rheumatoid factor, previously also associated with damage progression in general. 11, 12 If local treatment of swelling and tenderness could prevent later joint damage, this would be especially beneficial in high risk patients. This is illustrated by the fact that the attributable risk of having swelling and pain at least once is only 3 per 100 joints in ACPA and RF negative patients compared to 17 per 100 joints in ACPA and RF positive patients. This means that if the effects of swelling and tenderness on joint damage could be prevented, this would result in a risk reduction of 17% in autoantibody positive patients compared to 3% in autoantibody negative patients. In two older cohorts 4,5 a high correlation between large joint damage and functional ability was found. Although, possibly due to DAS-targeted treatment, there was less severe damage in the patients who did show damage (median Larsen score 1) than in older cohorts (median Larsen score 3 in the Drossaers-Bakker cohort), we found a statistically significant correlation between large joint damage and functional ability. Probably related to our finding that damage per joint was less severe than in the older cohorts, the difference in HAQ between patients with or without large joint damage was not above the clinically significant level of 0.19-0.24. 13 As suggested by the analyses by tertile, this difference would most likely be bigger when a more stringent cut-off of large joint damage is used. The difference we found was largely attributable to damage of the wrists (data not shown), as most daily activities inventoried in the HAQ require use of the wrists. In small joints, the association between joint damage and functional ability increases in time, 14 so maybe this 8-year evaluation comes too soon to detect disabling joint damage. Because in this study baseline radiographs of the large joints or radiographs after 2 years are not available, we cannot determine when joint damage occurred. In theory, tenderness or swelling recorded in the first 2 years of the study might have been the result of early large joint damage. However, since large joint damage usually occurs later in the disease course and is usually preceded by small joint damage, [14] [15] [16] which was limited at baseline in our study, swelling and tenderness in the first 2 years after diagnosis are most likely to be the result of local synovitis, and not of joint damage. Of all large joints, 18% was damaged after 8 years without showing any signs of clinical synovitis in the first 2 years of treatment. This may indicate that such damage was the result of inflammation that occurred later in the disease stage, or perhaps of inflammation with subclinical synovitis. 10 We cannot confirm this as there were no other imaging techniques as part of the study protocol. Our experienced musculoskeletal radiologist differentiated between signs consistent with secondary osteoarthritis and signs consistent with primary OA, but it is not impossible that there are joints in the database that received a score of 1 due to primary OA signs. There was a small but statistically significant difference in disease 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39 activity over 8 years follow-up between patients with and without any large joint damage. However, this was not found for systemic inflammation as represented by the ESR. Another potential limitation is that these data from the BeSt cohort are based on a selection of patients who had radiographs available and remained under follow-up. There was no significant difference in large joint swelling and tenderness over 8 years between patients who remained in follow-up with or without radiographs. This indicates that we have no evidence of selection bias, which might influence the association between early large joint swelling and tenderness and later large joint damage. Compared to patients who remained in follow-up, patients no longer in follow-up in the BeSt study were on average older and had slightly higher disease activity at baseline. It is likely that these patients would have had worse functional ability but also possible that they have more large joint damage at year 8 than the patients still under follow-up. This would not affect the association between large joint damage and functional ability that we found.
In conclusion: in this treat to target cohort, early local signs of inflammation are independently associated with local damage in the same large joints after 8 years, although disease activity over 8 years was similar for both patients with and without large joint damage. More than small joint damage, large joint damage is associated with functional disability. This suggests that better suppression of local inflammation could prevent future damage and disability, which would be especially relevant in autoantibody positive patients, as they have an increased risk of large joint damage. Additional studies to determine the long term effects of local treatment are needed to give more insight into whether this can indeed prevent large joint damage and disability. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39   31 Large joint synovitis and local large joint damage 2
